首页> 美国卫生研究院文献>other >Contribution of Genome-Wide Association Studies to Scientific Research: A Pragmatic Approach to Evaluate Their Impact
【2h】

Contribution of Genome-Wide Association Studies to Scientific Research: A Pragmatic Approach to Evaluate Their Impact

机译:全基因组关联研究对科学研究的贡献:一种评估其影响的实用方法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The factual value of genome-wide association studies (GWAS) for the understanding of multifactorial diseases is a matter of intense debate. Practical consequences for the development of more effective therapies do not seem to be around the corner. Here we propose a pragmatic and objective evaluation of how much new biology is arising from these studies, with particular attention to the information that can help prioritize therapeutic targets. We chose multiple sclerosis (MS) as a paradigm disease and assumed that, in pre-GWAS candidate-gene studies, the knowledge behind the choice of each gene reflected the understanding of the disease prior to the advent of GWAS. Importantly, this knowledge was based mainly on non-genetic, phenotypic grounds. We performed single-gene and pathway-oriented comparisons of old and new knowledge in MS by confronting an unbiased list of candidate genes in pre-GWAS association studies with those genes exceeding the genome-wide significance threshold in GWAS published from 2007 on. At the single gene level, the majority (94 out of 125) of GWAS-discovered variants had never been contemplated as plausible candidates in pre-GWAS association studies. The 31 genes that were present in both pre- and post-GWAS lists may be of particular interest in that they represent disease-associated variants whose pathogenetic relevance is supported at the phenotypic level (i.e. the phenotypic information that steered their selection as candidate genes in pre-GWAS association studies). As such they represent attractive therapeutic targets. Interestingly, our analysis shows that some of these variants are targets of pharmacologically active compounds, including drugs that are already registered for human use. Compared with the above single-gene analysis, at the pathway level GWAS results appear more coherent with previous knowledge, reinforcing some of the current views on MS pathogenesis and related therapeutic research. This study presents a pragmatic approach that helps interpret and exploit GWAS knowledge.
机译:全基因组关联研究(GWAS)对于理解多因素疾病的事实价值是一个激烈争论的问题。开发更有效的疗法的实际后果似乎并非指日可待。在这里,我们建议对这些研究产生多少新生物学进行务实和客观的评估,尤其要注意可以帮助确定治疗目标优先级的信息。我们选择多发性硬化症(MS)作为范例疾病,并假设在GWAS候选基因研究中,每个基因选择背后的知识反映了GWAS出现之前对该疾病的了解。重要的是,这种知识主要基于非遗传的表型依据。我们通过面对早于GWAS的关联研究中的候选基因的公正列表与那些自2007年以来发表的GWAS中超出基因组范围的显着性阈值的基因进行对抗,对MS中的新旧知识进行了单基因和通路导向的比较。在单基因水平上,从未发现在GWAS之前的关联研究中,大多数(125个中的94个)GWAS发现的变体是合理的候选对象。在GWAS之前和之后的清单中同时存在的31个基因可能特别受关注,因为它们代表了与疾病相关的变体,其病原学相关性在表型水平上得到支持(即,表型信息指导他们选择作为表型候选基因)。 GWAS之前的协会研究)。因此,它们代表有吸引力的治疗靶标。有趣的是,我们的分析表明,这些变体中的一些是药理活性化合物的靶标,包括已经注册用于人类的药物。与上述单基因分析相比,在途径水平上,GWAS结果与以前的知识更加一致,从而加强了对MS发病机理和相关治疗研究的一些当前观点。这项研究提出了一种实用的方法,可以帮助解释和利用GWAS知识。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号